Compare Marsh & McLennan Companies, Inc. (MRSH) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Marsh & McLennan Companies, Inc. trades at $183.86 (market cap $84.47B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 86.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MRSH | MRVI | |
|---|---|---|
Market Cap | $84.47B | $972.90M |
Volume | 3,662,234 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $203.85 | $9.00 |
52-Week Low | $157.32 | $2.83 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $105.15B | $1.08B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $178.40, up 1.05% today, with a bullish technical signal and recent earnings beats. The stock shows strong fundamentals with a P/E of 21.61, net income margin of 14.24%, and consistent revenue growth to $27.0B in 2025. Recent acquisition of Accel Holdings (Business Wire, 2026-10-02) enhances its advisory services, while analyst consensus is a 'Hold' with a $202.71 price target. Cash flow remains positive at $486M in 2025, supporting dividend payments.
Outlook is cautiously optimistic; the stock offers growth potential from strategic acquisitions and solid profitability, but risks include high P/B of 5.56 and competitive pressures. Investors should weigh the 13.6% upside to the consensus target against overbought RSI levels and margin compression risks in 2026 forecasts.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
